top of page
About Colorectal Cancer In SF


SF CAN seeks to reduce new liver cancer cases and liver cancer deaths in San Francisco by 50 percent.

We will do this by reducing the impact of viral hepatitis.

Task Force & Research



strategy: Hepatitis B (HBV) and Hepatitis C (HCV) elimination

The goals of the Liver Cancer Task Force are to reduce liver cancer (hepatocellular  or HCC) morbidity and mortality in San Francisco through:

  1. Hepatitis C virus (HCV) elimination

  2. Hepatitis B virus (HBV) elimination

  3. Increased liver cancer screening

  4. Improved access to state-of-the-art liver cancer treatment

  5. Non-alcoholic fatty liver disease (NAFLD) education, screening and referral to care (new goal for Year 5).

Data Collection
With a multi-partnership model, we aim to collect data we can translate into interventions in SF.

  1. Estimate the number of people with HCV and HBV

  2. Analyze the current quality of care for HCV and HBV patient

  3. Establish rates of HCC screening

  4. Identify major gaps in care of HCV, HBV and HCC, especially in minority populations.



  • Increase HCV and HBV diagnosis and treatment

  • Improve HCC screening and treatment

  • Design NAFLD detection and referral strategies


Rena Fox, MD, Dept. of Medicine, UCSF

Tung Nguyen, MD, Dept. of Medicine, UCSF

Liver Cancer Task Force – Partners, Products and Affiliated Organizations 


how can I get involved?

for providers

Hepatitis B ECHO Program

Case-based learning sessions between HBV specialists and primary care providers.  


Become a primary care expert on hepatitis B (Earn FREE CME)

3rd Tuesday of every month. 12:30-1:30pm PDTTo register email

UCSF Hepatitis C Project ECHO Program
Project ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management that empowers clinicians everywhere to provide better care to more people, right where they live.

latest research

Overall Progress Made and Major Achievements (07/01/19-06/30/20)

Community Partnerships and Outreach:

Among our major achievements this year, we produced analyses of large segments of the SF population with HCV and HBV, further expanded peer-education to improve HCV treatment in SF, and promoted HBV testing, prevention and treatment in Asian-American communities.


We also identified patients with HIV and untreated HCV coinfection, put on an SF-wide research symposium on local HCV interventions, established a new partnership with Kaiser Permanente SF, and successfully applied for competitive new funding to develop a novel program of identifying patients with NAFLD in primary care.


Publications and Poster Presentations:

  1. Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. Facente SN, Grebe E, Burk K, Morris MD, Murphy EL, Mirzazadeh A, Smith AA, Sanchez MA, Evans JL, Nishimura A, Raymond HF; End Hep C SF.PLoS One. 2018 Apr 11;13(4):e0195575. doi: 10.1371/journal.pone.0195575. eCollection 2018.PMID: 29641546 Free PMC article.  

  2. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated. Morris MD, Mirzazadeh A, Evans JL, Briceno A, Coffin P, Hahn JA, Page KA.Drug Alcohol Depend. 2019 May 1;198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. Epub 2019 Feb 27.PMID: 30921649 Free PMC article.  

  3. Rivadeneira NA, Hoskote M, Le GM, Nguyen TT, Nápoles AM, Pasick RJ, Sarkar U, Hiatt RA. Advancing Cancer Control in San Francisco: Cancer Screening in Under-Represented Populations. Am J Prev Med. 2020 Jan;58(1):e1-e9. doi: 10.1016/j.amepre.2019.08.024. PMID: 31862104; PMCID: PMC7173710. 

  4. Chu JN, Stewart SL, Gildengorin G, Wong C, Lam H, McPhee SJ, Chen MS, Bastani R, Maxwell AE, Taylor VM, Nguyen TT. Effect of a media intervention on hepatitis B screening among Vietnamese Americans. Ethn Health. 2019 Oct 14:1-14. doi: 10.1080/13557858.2019.1672862. Epub ahead of print. PMID: 31608675; PMCID: PMC7162532. 

  5. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. J Gen Intern Med. 2019 10; 34(10):2005-2013. Kim NJ, Locke CJ, Park H, Magee C, Bacchetti P, Khalili M. PMID: 30238404. View in: PubMed   

  6. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. Ann Hepatol. 2018 May-June; 17(3):413-418. Beck KR, Kim NJ, Khalili M. PMID: 29735789. View in: PubMed    

  7. Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers. J Clin Gastroenterol. 2017 Aug; 51(7):626-631. Mukhtar NA, Kathpalia P, Hilton JF, Lau G, Yu A, Grumbach K, Nguyen TT, Chan D, Khalili M. PMID: 27811627.

  8. Mukhtar NA, Fox RK. Hepatitis C Virus Cure and Obesity: Watch the Weight.J Gen Intern Med. 2020 Oct;35(10):2836-2837. doi: 10.1007/s11606-020-06004-9. PMID: 32632793  

  9. Wilson EC, Turner C, Lin J, McFarland W, Burk K, Raymond HF. Hepatitis C seroprevalence and engagement in related care and treatment among trans women. J Viral Hepat. 2019 Jul;26(7):923-925. doi: 10.1111/jvh.13089. Epub 2019 Mar 27. PMID: 30809884. 

  10. Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS. Localized US Efforts to Eliminate Hepatitis C. Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009. PMID: 29778257. 


liver cancer task force

Partner Organizations
  • End Hep C SF 

  • SF Hep B Free 

  • DeLIVER Van 

  • California Pacific Medical Center 

  • Kaiser Permanente San Francisco 

  • San Francisco Department of Public Health  

  • UCSF Division of General Internal Medicine 

  • UCSF Division of Hepatology 

  • UCSF Division of GI Oncology 

  • Zuckerberg San Francisco General Hospital, Division of Hepatology 

partner organizations

bottom of page